Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pak Fah Yeow InternationalHKSE:00239 80 EV-to-FCF is 3.56 as of Aug. 05, 2026, which is 61% below its 10-year median of 9.05. GuruFocus rates HKSE:00239 with a GF Score™ of 80/100 and a GF Value™ of HK$2.17 (Fairly Valued). The stock has 3 warning signs investors should review. Among 571 Drug Manufacturers companies, Pak Fah Yeow International ranks better than 93.35% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pak Fah Yeow International's Enterprise Value is HK$400.4 Mil.
Pak Fah Yeow International's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$112.3 Mil. Therefore, Pak Fah Yeow International's EV-to-FCF for today is 3.56.
The historical rank and industry rank for Pak Fah Yeow International's EV-to-FCF or its related term are showing as below:
HKSE:00239'
s EV-to-FCF Range Over the Past 10 Years
Min: 1.84 Med: 9.05 Max: 62.36
Current: 3.56
During the past 13 years, the highest EV-to-FCF of Pak Fah Yeow International was 62.36. The lowest was 1.84. And the median was 9.05.
HKSE:00239's EV-to-FCF is ranked better than 93.35% of 571
companies
in the Drug Manufacturers industry
Industry Median: 21.2
vs HKSE:00239: 3.56
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pak Fah Yeow International (HKSE:00239) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pak Fah Yeow International's PE Ratio (TTM) for today is calculated as:
Pak Fah Yeow International's share price for today is HK$2.375.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pak Fah Yeow International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.293.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Pak Fah Yeow International EV-to-FCF Related Terms
Pak Fah Yeow International EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Pak Fah Yeow International's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pak Fah Yeow International EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pak Fah Yeow International's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Pak Fah Yeow International's EV-to-FCF falls into.
Pak Fah Yeow International's current Enterprise Value is HK$400.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pak Fah Yeow International's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$112.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pak Fah Yeow International (HKSE:00239) has a EV-to-FCF of 3.56 as of Aug. 05, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pak Fah Yeow International and its competitors. This is 61% below median its historical median of 9.05. Over the past decade, Pak Fah Yeow International's EV-to-FCF has ranged from 1.84 to 62.36. According to the industry distribution chart, Pak Fah Yeow International ranks #38 out of 571 companies in the Drug Manufacturers industry, placing it in the top 6.7%.
Is Pak Fah Yeow International's EV-to-FCF too high?
Pak Fah Yeow International's current EV-to-FCF of 3.56 is 61% below median its 10-year median of 9.05. Over the past 10 years, this metric has ranged from a low of 1.84 to a high of 62.36. The Drug Manufacturers industry median EV-to-FCF is 21.20. Pak Fah Yeow International's value of 3.56 is 83.2% below this industry median. Based on the distribution chart, Pak Fah Yeow International ranks #38 out of 571 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Pak Fah Yeow International has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pak Fah Yeow International's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Pak Fah Yeow International ranks #38 out of 571 companies for EV-to-FCF. This places Pak Fah Yeow International in the top 7% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 21.20. Pak Fah Yeow International's value of 3.56 is 83.2% below this benchmark. Historically, Pak Fah Yeow International's own EV-to-FCF has ranged from 1.84 to 62.36 over the past decade. While the company's 10-year median is 9.05 vs. the industry median of 21.20, Pak Fah Yeow International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.20, based on 571 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pak Fah Yeow International's current EV-to-FCF of 3.56 is 83.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pak Fah Yeow International and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pak Fah Yeow International's current EV-to-FCF is 3.56, which is 61% below median its own 10-year median of 9.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pak Fah Yeow International stock overvalued right now?
Based on GuruFocus' analysis, Pak Fah Yeow International (HKSE:00239) is currently considered Fairly Valued. The stock's GF Value™ is HK$2.17, compared to a current price of HK$2.38 — trading 9.4% above its estimated fair value. The current EV-to-FCF is 3.56, which is 61% below median its 10-year median of 9.05 and 83.2% below the Drug Manufacturers industry median of 21.20. Pak Fah Yeow International's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Pak Fah Yeow International (HKSE:00239), the current EV-to-FCF is 3.56 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pak Fah Yeow International (HKSE:00239) Overvalued in 2026?
Based on GuruFocus' analysis, Pak Fah Yeow International stock appears to be overvalued.
The current stock price of HK$2.38 is trading 9.4% above its estimated GF Value™ of HK$2.17.
GuruFocus considers Pak Fah Yeow International to be Fairly Valued.
Key valuation signals for HKSE:00239:
EV-to-FCF: 3.56 (61% below median its 10-year median of 9.05)
GF Value™: HK$2.17 vs. price of HK$2.38 (9.4% above fair value)
Industry Position: 83.2% below the Drug Manufacturers median (#38 of 571)
No single metric tells the full story. See the HKSE:00239 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pak Fah Yeow International Ltd, with its subsidiaries, is engaged in the manufacture and distribution of healthcare products, including Hoe Hin branded products. It also engages in real estate investment and treasury investment businesses. It has three business segments, namely healthcare, property investments, and treasury investments. The Company derives the majority of its revenues from the Healthcare segment.The Groups businesses cover Hong Kong, Macau, other regions in the Peoples Republic of China (the PRC or Chinese Mainland), Southeast Asia, North America and the United Kingdom.
80GF Score
Get the complete analysis for HKSE:00239
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00239 has been successfully added to your 
